• Melena D Bellin, Gregory J Beilman, Ty B Dunn, Timothy L Pruett, Srinath Chinnakotla, Joshua J Wilhelm, Anh Ngo, David M Radosevich, Martin L Freeman, Sarah J Schwarzenberg, A N Balamurugan, Bernhard J Hering, and David E R Sutherland.
• Schulze Diabetes Institute, University of Minnesota, Minneapolis, MN 55455, USA. bell0130@umn.edu
• Pancreas. 2013 Mar 1;42(2):317-21.

ObjectivesIslet autotransplantation (IAT) is performed in nondiabetic patients with chronic pancreatitis at the time of total pancreatectomy (TP) to minimize risk of postoperative diabetes. The role of TP-IAT in patients with chronic pancreatitis and C-peptide-positive diabetes is not established. We postulate that IAT can preserve beta cell mass and thereby benefit patients with preexisting diabetes undergoing TP.MethodsPreoperative metabolic testing, islet isolation outcomes, and subsequent islet graft function were reviewed for 27 patients with diabetes mellitus and chronic pancreatitis undergoing TP-IAT. The relationships between the results of preoperative metabolic testing and islet isolation outcomes were explored using regression analysis.ResultsMean islet yield was 2060 (SD, 2408) islet equivalents/kg. Peak C-peptide (from mixed meal tolerance testing) was the strongest predictor of islet yield, with higher stimulated C-peptide levels associated with greater islet mass. Half of the patients who had C-peptide levels measured after transplantation demonstrated C-peptide production at a level that conveys protective benefit in type 1 diabetes (≥ 0.6 ng/mL).ConclusionsThese findings provide proof of concept that significant islet mass can be isolated in patients with chronic pancreatitis and C-peptide-positive diabetes mellitus undergoing TP-IAT. Stimulated C-peptide may be a useful marker of islet mass before transplantation in these patients.

37 keywords...

hide…